Literature DB >> 17931158

Cationic liposomes as vaccine adjuvants.

Dennis Christensen1, Karen S Korsholm, Ida Rosenkrands, Thomas Lindenstrøm, Peter Andersen, Else Marie Agger.   

Abstract

Cationic liposomes are lipid-bilayer vesicles with a positive surface charge that have re-emerged as a promising new adjuvant technology. Although there is some evidence that cationic liposomes themselves can improve the immune response against coadministered vaccine antigens, their main functions are to protect the antigens from clearance in the body and deliver the antigens to professional antigen-presenting cells. In addition, cationic liposomes can be used to introduce immunomodulators to enhance and modulate the immune response in a desirable direction and, thereby, represent an efficient tool when designing tailor-made adjuvants for specific disease targets. In this article we review the recent progress on cationic liposomes as vehicles, enhancing the effect of immunomodulators and the presentation of vaccine antigens.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17931158     DOI: 10.1586/14760584.6.5.785

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  16 in total

Review 1.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

2.  Reducing the Visibility of the Vector/DNA Nanocomplexes to the Immune System by Elastin-Like Peptides.

Authors:  Faranak S Nouri; Xing Wang; Xuguang Chen; Arash Hatefi
Journal:  Pharm Res       Date:  2015-03-31       Impact factor: 4.200

3.  Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice.

Authors:  Hong Yu; Karuna P Karunakaran; Xiaozhou Jiang; Caixia Shen; Peter Andersen; Robert C Brunham
Journal:  Infect Immun       Date:  2012-01-30       Impact factor: 3.441

Review 4.  mRNA-based therapeutics: powerful and versatile tools to combat diseases.

Authors:  Shugang Qin; Xiaoshan Tang; Yuting Chen; Kepan Chen; Na Fan; Wen Xiao; Qian Zheng; Guohong Li; Yuqing Teng; Min Wu; Xiangrong Song
Journal:  Signal Transduct Target Ther       Date:  2022-05-21

5.  A novel liposome-based adjuvant CAF01 for induction of CD8(+) cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice.

Authors:  Gregers Jacob Gram; Ingrid Karlsson; Else Marie Agger; Peter Andersen; Anders Fomsgaard
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

6.  Adjuvants induce distinct immunological phenotypes in a bovine tuberculosis vaccine model.

Authors:  H Martin Vordermeier; Gillian S Dean; Ida Rosenkrands; Else M Agger; Peter Andersen; Daryan A Kaveh; R Glyn Hewinson; Philip J Hogarth
Journal:  Clin Vaccine Immunol       Date:  2009-07-29

Review 7.  Actinoporins: From the Structure and Function to the Generation of Biotechnological and Therapeutic Tools.

Authors:  Santos Ramírez-Carreto; Beatriz Miranda-Zaragoza; Claudia Rodríguez-Almazán
Journal:  Biomolecules       Date:  2020-04-02

8.  The role of nanoliposome bilayer composition containing soluble leishmania antigen on maturation and activation of dendritic cells.

Authors:  Sara Shokooh Saremi; Maryam Shahryari; Razieh Ghoorchian; Hamed Eshaghian; Seyed Amir Jalali; Amin Reza Nikpoor; Mahmoud Reza Jafari; Ali Badiee
Journal:  Iran J Basic Med Sci       Date:  2018-05       Impact factor: 2.699

9.  TRPM2 links oxidative stress to NLRP3 inflammasome activation.

Authors:  Zhenyu Zhong; Yougang Zhai; Shuang Liang; Yasuo Mori; Renzhi Han; Fayyaz S Sutterwala; Liang Qiao
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  Effective usage of cationic derivatives of polyprenols as carriers of DNA vaccines against influenza virus.

Authors:  Anna Stachyra; Monika Rak; Patrycja Redkiewicz; Zbigniew Madeja; Katarzyna Gawarecka; Tadeusz Chojnacki; Ewa Świeżewska; Marek Masnyk; Marek Chmielewski; Agnieszka Sirko; Anna Góra-Sochacka
Journal:  Virol J       Date:  2017-09-02       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.